Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

REGN1979 shows good activity in pretreated aggressive B-NHL

Publish date:: January 15, 2020

Key clinical point: REGN1979 showed strong activity against relapsed/refractory aggressive B-cell non-Hodgkin lymphomas.

Major finding: The overall response rate among patients with follicular lymphoma was 95%.

Study details: A phase 1, dose-escalation study of 110 patients with aggressive-histology B-cell lymphomas.

Disclosures: The study is supported by Regeneron Pharmaceuticals. Dr. Bannerji reported research funding, travel support, and consulting fees from Regeneron and others.

Citation:

Bannerji R et al. ASH 2019, Abstract 762.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,